USFDA clears Plursitem for expanded access program

Patients suffering from critical limb ischemia can now benefit without being part of clinical trials

By DAVID BRUMMER
January 10, 2018 16:48
1 minute read.
A Pluristem scientist in the process of making its cell products and a look at the final product its

A Pluristem scientist at work.. (photo credit: PLURISTEM)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The US Food & Drug Administration has cleared Pluristem Therapeutics’ Expanded Access Program for the use of its PLX-PAD cell treatment in patients with critical limb ischemia.

The Haifa-based firm’s patented PLX-PAD placental cell therapy – which encourages the secretion of a range of therapeutic proteins and includes the growth of blood vessels and delivering oxygenated blood to damaged tissue to encourage the body to trigger its own repair mechanisms – will be made available to a limited number of Rutherford Category 5 critical limb ischemia (CLI) patients (those in danger of losing a limb due to non-healing ulcers and gangrene) in the US, who are unsuitable for vascularization and cannot take part in the company’s ongoing Phase III clinical study.

Be the first to know - Join our Facebook page.


Pluristem’s PLX-PAD program has already been selected for accelerated approval in the FDA’s Fast Track Designation and the European Medicines Agency’s Adaptive Pathways program.

“This is a true vote of confidence by the FDA in our cell therapy and a landmark achievement for Pluristem,” said Yaky Yanay, co-CEO and president of Pluristem. “It gives us the ability to begin treatments using our cell product, offering treatment to certain CLI patients who have poor therapeutic options, while also collecting real-world data alongside our ongoing Phase III clinical study.”

The FDA’s decision may also entitle Pluristem to be compensated for the costs of treatment, which could then be reinvested into further research in developing effective cell therapies with the potential to aid millions of patients worldwide.

This article was written in cooperation with Pluristem Therapeutics.

Related Content

August 12, 2018
Israel seeks early re-tender of mining rights to shore up Dead Sea

By REUTERS